Companies / Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc.
TALSTRMLCIK 1827506
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| May 11, 2021 | Agarwala Sandip Director | Buy Open-market buy | Common Stock | $4.00M | +235K +7.87% | 3,220,775 | high |
| May 11, 2021 | Longitude Capital Partners III, LLC 10% owner | Buy Open-market buy | Common Stock | $4.00M | +235K +7.87% | 3,220,775 | high |
| Jan 29, 2024 | McDade Mark Director | Buy Open-market buy | Common Stock | $3.25M | +100K +28.70% | 448,431 | high |
| Aug 22, 2022 | Ildstad Suzanne Executive | Sell Open-market sale | Common Stock | $1.47M | -525K -14.56% | 3,081,446 | medium |
| May 11, 2021 | Clarus Defined Exit I, L.P. 10% owner | Buy Open-market buy | Common Stock | $270.6K | +16K +0.33% | 4,875,730 | medium |
| May 11, 2021 | Clarus Lifesciences III, L.P. 10% owner | Buy Open-market buy | Common Stock | $270.6K | +16K +0.33% | 4,875,730 | medium |
| Oct 27, 2023 | Castelein Caley Director | Buy Open-market buy | Common Stock | $229.9K | +16K +3.16% | 516,519 | medium |
| Apr 17, 2023 | Ildstad Suzanne Executive | Sell Open-market sale | Common Stock | $213.5K | -100K -3.27% | 2,954,353 | medium |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TALS | common | 89157D105 |